<div id="readability-page-1"><div>Bragar Eagel &amp; Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Telix (TLX) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Telix and would like to discuss your legal rights, call Bragar Eagel &amp; Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, Aug. 23, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel &amp; Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Telix Pharmaceuticals Limited (“Telix” or the “Company”) (NASDAQ:TLX) on behalf of Telix stockholders. Our investigation concerns whether Telix has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On July 22, 2025, Telix disclosed receipt of a subpoena from the U.S. Securities and Exchange Commission, &#34;seeking various documents and information primarily relating to the Company's disclosures regarding the development of the Company's prostate cancer therapeutic candidates.&#34; On this news, Telix's American Depositary Receipt (&#34;ADR&#34;) price fell $1.70 per ADR, or 10.44%, to close at $14.58 per ADR on July 23, 2025. If you purchased or otherwise acquired Telix shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel &amp; Squire, P.C.: Bragar Eagel &amp; Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes. Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X. Contact Information: Bragar Eagel &amp; Squire, P.C. Brandon Walker, Esq. Marion Passmore, Esq. (212) 355-4648 investigations@bespc.com www.bespc.com <img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVeE5qZzJOQ00zTVRFeE9EazFJekl4TURBek9UZz0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVeE5qZzJOQ00zTVRFeE9EazFJekl4TURBek9UZz0"/> <img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NGI0NWI4ZjUtYTUyMy00NTFhLWFiMGItODc5MDdmMGFjNTcyLTExMTE5NjktMjAyNS0wOC0yMy1lbg==/tiny/Bragar-Eagel-Squire.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NGI0NWI4ZjUtYTUyMy00NTFhLWFiMGItODc5MDdmMGFjNTcyLTExMTE5NjktMjAyNS0wOC0yMy1lbg==/tiny/Bragar-Eagel-Squire.png"/> <img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/29481954-f2ff-4756-b5a9-d982a6497bd0/small/bes-mark-jpg.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="150" height="75" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/29481954-f2ff-4756-b5a9-d982a6497bd0/small/bes-mark-jpg.jpg"/></div></div>

Bragar Eagel & Squire, P.C. 正在代表其股東調查 Telix Pharmaceuticals Limited，原因是可能違反聯邦證券法。此次調查是由於 Telix 披露了來自 SEC 的傳票，涉及其前列腺癌治療候選藥物，這導致其 ADR 價格下跌了 10.44%。遭受損失的投資者被鼓勵聯繫該公司以尋求法律選項

TELIX ALERT: Bragar Eagel & Squire, P.C. is Investigating Telix Pharmaceuticals Limited on Behalf of Telix Stockholders and Encourages Investors to Contact the Firm

TELIX 警報：Bragar Eagel & Squire, P.C. 正在代表 Telix Pharmaceuticals 的股東進行調查，並鼓勵投資者與該律所聯繫